Home » Research team receives $2 million grant from NIH
August 21, 2009 – Texas Children’s Hospital
Marilyn Hockenberry, Ph.D., nurse-researcher and director of Texas Children’s Center for Clinical Research and professor of pediatrics at Baylor College of Medicine, and colleagues on her Texas Children’s Cancer Center research team have received a five-year RO1 grant totaling over $2 million from the National Institutes of Nursing Research—an arm of the National Institutes of Health.
In collaboration with Ki Moore, Ph.D., and her research team at the University of Arizona, the researchers will follow children with acute lymphoblastic leukemia who receive methotrexate for treatment. The drug, which fights cancer, can also damage non-malignant cells in the central nervous system, resulting in cognitive and academic problems in children. The team hopes their work will lead to early interventions to prevent problems for pediatric cancer patients in the future.
The team receiving the RO1 grant includes (left to right) Dr. Mary Ann Gregurich, Kathy McCarthy, Olga Taylor, Meredith Scarberry and Marilyn Hockenberry. This group will work together to study the cognitive side effects of a cancer-fighting medication.
“This grant allows us to continue or funded research with Dr. Moore to explore measures of central nervous system tissue damage in children with leukemia,” said Hockenberry. “Our work in this area has one of the largest longitudinal cohorts of children with leukemia in existence, and we continue to pave the way for understanding the long-term effects of leukemia treatment on the brain.”